PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022
London (PRWEB) September 16, 2013 -- PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022
Summary
GlobalData has released its new Country report, “PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.
GlobalData is following during this forecast will likely not launch in India. However, the domestic company, Biocon, has developed and gained approval for the biologic Alzumab. In January 2013, this CD6 suppressant gained Indian drug approva, but will not launch until late Q3/early Q4, according to Biocon. Since Alzumab is an IV formulation, we expect it to be priced similarly to Remicade. This therapy will provide PsO patients a suitable option for symptom relief. Therefore, its uptake will provide additional revenue to the Indian PsO market.
Scope
- Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the India including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in India from 2012 to 2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the India Psoriasis market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012 to 2022 in India.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 17
4 Disease Management 18
4.1 Treatment Overview 19
4.2 India 24
4.2.1 Diagnosis 24
4.2.2 Clinical Practice 24
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
5.3 Product Profiles – Major Brands 28
5.3.1 Taclonex (calcipotriene hydrate and betamethasone dipropionate) 28
5.3.2 Methotrexate Sodium (numerous generic names) 32
5.3.3 Minor Therapeutic Drug Classes Used in Psoriasis 36
5.3.4 Non-Pharmacological Therapy 37
6 Opportunity and Unmet Need 39
6.1 Overview 39
6.2 Unmet Needs 40
6.2.1 Improved Drug Safety and Efficacy Profiles 40
6.2.2 Biomarkers for Predicting Remission 41
6.2.3 More Cost-Effective Therapies Through Oral Formulation and Biosimilars 41
6.2.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 42
6.2.5 An Effective Biologic/Systemic Topical Therapy 42
6.2.6 More Effective Treatment for Mild Psoriasis, Specifically UV Therapies 43
6.2.7 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 43
6.3 Opportunities 44
6.4 Unmet Needs Gap Analysis 44
6.4.1 Predictive Tools for Diagnosis and Treatment 45
6.4.2 Target Specificity 45
6.4.3 Topical Biologic/Systemic Therapeutic Options 46
6.4.4 Helping Patients with Psychological Issues Associated with Psoriasis 46
7 Pipeline Assessment 47
7.1 Overview 47
7.2 Promising Drugs in Clinical Development 48
7.2.1 Alzumab (itolizumab) 50
7.2.2 Phase II Pipeline Products 55
7.2.3 Phase I Pipeline Products 57
7.2.4 Biosimilars Pipeline Products 58
8 Market Outlook 61
8.1 India 61
8.1.1 Forecast 61
8.1.2 Key Events 64
8.1.3 Drivers and Barriers 64
9 Appendix 67
9.1 Bibliography 67
9.2 Abbreviations 74
9.3 Methodology 78
9.4 Forecasting Methodology 78
9.4.1 Diagnosed Psoriasis Patients 78
9.4.2 Percent Drug-Treated Patients 79
9.4.3 Drugs Included in Each Therapeutic Class 79
9.4.4 General Pricing Assumptions 80
9.4.5 Individual Drug Assumptions 81
9.4.6 Generic Erosion 82
9.4.7 Pricing of Pipeline agents 82
9.5 Physicians and Specialists Included in this Study 83
9.6 Primary Research – Prescriber Survey 84
9.7 About the Authors 85
9.7.1 Analysts 85
9.7.2 Global Head of Healthcare 86
9.8 About GlobalData 87
9.9 Disclaimer 87
1.1 List of Tables
Table 1: Immune Cells Involved in Lesions 14
Table 2: Symptoms of Psoriasis 17
Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis 21
Table 4: Treatment Guidelines for Psoriasis 22
Table 5: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2012 23
Table 6: Leading Treatments for Psoriasis, 2013 27
Table 7: Product Profile – Taclonex 29
Table 8: Taclonex SWOT Analysis, 2013 31
Table 9: Product Profile – Methotrexate 33
Table 10: Methotrexate SWOT Analysis, 2013 35
Table 11: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2013 36
Table 12: Overall Unmet Needs in Psoriasis – Current Level of Attainment 40
Table 13: Clinical Unmet Needs in Psoriasis – Gap Analysis, 2013 45
Table 14: Psoriasis – Phase Pipeline, 2013 48
Table 15: Comparison of Therapeutic Classes in Development for Psoriasis, 2013 49
Table 16: Product Profile – Alzumab 51
Table 17: Alzumab SWOT Analysis, 2013 53
Table 18: Global Sales Forecasts ($) for Alzumab, 2012–2022 54
Table 19: Phase II Psoriasis Pipeline, 2013 55
Table 20: Phase I Psoriasis Pipeline, 2013 57
Table 21: Biosimilars Pipeline, 2013 60
Table 22: Sales Forecasts ($) for Psoriasis in India, 2012–2022 62
Table 23: Key Events Impacting Sales for Psoriasis in India 2012–2022 64
Table 24: Psoriasis Market in India – Drivers and Barriers, 2012–2022 64
Table 25: Physicians Surveyed, By Country 84
1.2 List of Figures
Figure 1: Psoriatic Plaque on Elbow of Patient 13
Figure 2: The Three Layers of the Skin and Associated Structures 15
Figure 3: Healthy Skin Versus Psoriatic Skin 16
Figure 4: BB-UVB Therapy Guidelines, According to the AAD 38
Figure 5: NB-UVB Therapy Guidelines, According to the AAD 38
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2012–2022 48
Figure 7: Estimated Sales of Biosimilars vs. Their Branded Counterparts in Psoriasis, 2012–2022 59
Figure 8: Sales for Psoriasis in India by Drug Class, 2012–2022 63
Read the full report:
PharmaPoint: Psoriasis - India Drug Forecast and Market Analysis to 2022
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com
Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]
Share this article